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Abstract
Vasovagal syncope can persist for decades and recur sporadically but many patients appear 
to improve after being seen in specialty clinics. The absence of specific and proven effective 
therapy raises the possibility that this might be due to regression to the mean or to a placebo 
effect. However, analysis using the Poisson distribution indicates the extreme unlikeliness that 
regression to the mean is the explanation. A main cause of the placebo effect is expectancy. 
Subject expectancy is the influence of the subject’s anticipation of benefit on outcomes, and  
observer expectancy is the influence of investigator or physician attitudes and behavior on subject  
response. Ample data support the role of expectancy in outcomes of syncope patients. Moreover, 
expectancy can vary depending on the type of ineffective intervention. Interestingly, studies in 
which patients are blinded but the investigator is not show similar patient benefits compared 
with completely open label studies consistent with a strong observer expectancy effect due to 
physician-subject interaction. These results suggest the paramount importance of properly  
conducted randomized clinical trials in assessing biomedical interventions, and also illuminate  
the powerful potential of studies aimed at enhancing the expectancy effect on patient outcome. 
(Cardiol J 2014; 21, 6: 637–642)
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The clinical problem
One of the great challenges in assessing and 
treating vasovagal syncope (VVS) is its sporadic na-
ture. Numerous discussions suggest susceptibility 
of this patient population to the placebo effect. We 
believe the conversation needs to be recast. Place-
bo generally involves an implicit or explicit element 
of deliberate deception by physicians; this distracts 
investigators from seeing the opportunities of the 
real issue: the expectancy effect.
At least 40% of people have a vasovagal faint 
by age 60, and in most fainters, it is a recurring 
problem [1, 2]. In young and middle-aged commu-
nity populations, the median lifetime number of 
faints approximates 3–4, but clinical populations 
in observational and randomized trials often report 
a median of 10–20 lifetime faints. Only a minority 
faint once. Therefore, VVS is common, and com-
monly recurrent.
What is particularly interesting and germane 
is variation of syncope frequency within any single 
patient. For nearly 20 years, observational and in-
terventional studies have noted qualitatively that 
patients appear to fare better after being seen in 
specialty clinics than might be expected from their 
clinical history. This was first noticed in a series of 
retrospective observational studies from our center 
[3–5]; since then, this has been seen ubiquitously 
in single center and multicenter studies. It has led 
to randomized controlled trials being much larger 
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symptom burden in order to provide adequate 
power. The common conclusion is that a powerful 
placebo effect is at play, but is this the correct, or 
only, possibility?
Here, we review some common explanations 
for temporal variability in the clinical course of 
syndromes with paroxysmal presentations, then 
try to draw tentative conclusions about the nature 
of temporal variability in VVS.
The nature of clinical variance
Regression to the mean
Recurring events can be described with mathe-
matical modeling. Theoretically, some paroxy- 
smal events recur with a pattern of true temporal 
randomness, with independence of 1 event and 
another. Commonly, these events fit a Poisson 
distribution, which can be depicted by the classic 
survival curve well known in the medical literature. 
A related and common variant is the Weibull distri-
bution. Both assume a random series of events 
from the population of patients; that is, the random 
recurrence of syncope over time.
In random models, some events occur earlier 
and some later, leading to the appearance of long 
and short intervals between events, and periods 
of more and less frequent fainting. An observer 
might conclude that the syndrome is entering 
a quiescent phase when going from times of frequ-
ent to less frequent events. In truth, the apparent 
improvement in syncope frequency might simply 
be regression to the mean.
Placebo effect
The true placebo effect is a complex and com-
prehensive collection of factors [6–9]. Although the 
term is used widely, there is legitimate debate as 
to whether administering a purposefully deceptive 
intervention — the placebo proper — has any effect 
above non-biomedical but behavioral interventions 
and effects such as conditioning [6], expectancy [9], 
and physician behavior [7, 8, 10]. Kirsch originally 
hypothesized [9] that placebo effects are produced 
by a self-fulfilling effect. If a person believes that 
he or she will feel different, they actually feel 
different. This is termed “response expectancy”. 
Subjects who expect to feel better demonstrate 
subject response expectancy, while subjects whose 
physicians expect them to feel better demonstrate 
observer response expectancy.
Placebo effects can be observed in invasive 
and non-invasive studies, although there is debate 
whether a placebo intervention is better than no 
intervention at all [7, 8, 10]. Arthroscopic partial 
meniscectomy is frequently used to reduce symp-
toms due to a tear in a meniscus. The procedure 
is very common, with a widespread understanding 
that it is effective at reducing symptoms. However, 
Sihvonen et al. [11] performed a randomized con-
trolled study of arthroscopic meniscectomy com-
paring “real” to sham surgery. Personnel outside 
the operating room did not know the intervention 
allocation until completion of data analysis. At 
12 months, no significant difference in symptoms exi - 
sted between groups suggesting that a major aspect 
of symptom suppression was due to expectancy on 
the part of patients and surgeons. A clinical trial 
of back surgery for osteoporotic fractures came to 
the same conclusion [12].
The same effect occurs in hypertrophic ob-
structive cardiomyopathy patients undergoing 
pacemaker implantation. Initial reports concluded 
that permanent cardiac pacing reduced symptoms 
in these patients, but, in a double-blind randomized 
trial, Linde et al. [13] found no differences in chest 
pain, dyspnea or dizziness between active and ina-
ctive pacing. The placebo (and likely expectancy) 
effect is, therefore, a real response, that plays an 
important role in “treatment”.
Not everyone is susceptible to this type of pla-
cebo effect [14] raising the possibility of a genetic 
basis to the placebo effect, in general, and to syn-
cope, in particular. Furmark et al. [15] reported that 
the magnitude of the placebo response in patients 
with social anxiety disorder is linked to attenuation 
in amygdala excitability, which, in turn, is linked 
to specific alleles of the serotonin transporter and 
tyrosine hydroxylase. This mechanism may be of 
particular importance to syncope given the strongly 
suspected relationship between serotonin signaling 
and syncope. Similarly, Hall et al. [16] reported that 
polymorphisms in catechol-O-methyltransferase are 
associated with increased responsiveness to the pla-
cebo effect. This effect is likely due to an interaction 
with dopamine availability in the prefrontal cortex.
Variance in syncope presentation
In randomized clinical trials of VVS, about 
99% of patients faint in the year before random-
ization, but usually less than half faint in the next 
year. Numerous retrospective and prospective 
observational studies and randomized studies with 
a wide range of blinding, controls, and populations 
provide interesting test cases with which we can 
explore possible reasons for why people appear to 
stop fainting.
638 www.cardiologyjournal.org
Cardiology Journal 2014, Vol. 21, No. 6
Regression to the mean
The Poisson distribution permits estimating 
the distribution that characterizes events with low 
occurrence rates in time. Poisson originally derived 
it to describe gamblers’ wins and losses in a game 
with a low likelihood of wins. Some interesting 
historical applications included estimating the 
number of false convictions in early 19th century 
France, the likelihood of getting kicked by a horse 
in the Prussian army, and assessing whether fly-
ing bombs in World War II were targeting specific 
areas in Britain with either high or low rates of 
explosions.
The Poisson distribution can estimate the 
likelihood that a patient with a specific number of 
faints in 1 year will not faint in the next, all factors 
being unchanged. Most randomized clinical trials 
of syncope include patients who had fainted 
a median of 2–5 times in the preceding year, yet, in 
most studies, only a minority faint again the next 
year. For patients with 2, 3, 4, and 5 faints in the 
prior year, the probabilities of no faints in the next 
year are 14%, 5%, 1.8%, and 0.7%. Therefore, it 
seems exceedingly unlikely that the apparent im- 
provement in syncope patients is simply due to 
a statistical fluctuation in syncope frequency.
Improvement with no placebo
The ISSUE 1 study [17] was a prospective 
observational study in which all the enrolled 
subjects received an implantable loop recorder, 
and few received a specific intervention. There 
was a large reduction in the likelihood of subjects 
fainting, yet there was no placebo administered. 
Improvement occurred without deception or offer 
of clinical gain. In the PC trial, van Dijk et al. [18] 
reported that physical maneuvers reduced the 
likelihood of a syncope recurrence compared to 
no specific treatment. However, the control arm, 
whose treatment consisted generally of lifestyle 
and dietary suggestions of dubious biomedical 
value, also showed a reduction in syncope proba-
bility after study enrolment. That is, a lifestyle 
placebo appeared to have an effect on reducing 
syncope recurrences.
Similar effects are seen in open-label, random-
ized, pacemaker studies. For example, in the VASIS 
study [19], all patients fainted in the preceding year, 
with a median frequency of 3 faints per year, yet 
over an extended follow-up, fully 39% did not faint 
at all. Therefore, conservative treatment, without 
a known biological effect, provided sustained benefit. 
Again, a lifestyle placebo appears to have an effect 
on reducing syncope recurrences.
Ineffective treatment  
vs. no specific treatment
We reported a series of observational stu-
dies [3–5] in which some patients received what 
was imagined and conveyed as active treatment, 
while others did not. This was solely on the basis 
of physician’s clinical decision-making, and the 
medications subsequently were shown to be inef-
fective. Both groups showed a marked and similar 
reduction in the proportion of patients who fainted, 
providing evidence that administering biologically 
ineffective treatment (in good faith) is no better 
than no specific treatment. That is, a medical pla-
cebo appears to have no more powerful effect than 
interaction with a specialist physician [10].
Effect of placebo type
There are multiple observational studies and 
randomized trials that provide insight into invasive 
vs. non-invasive placebo. In the first Prevention of 
Syncope Trial [20] almost all patients fainted in the 
year before enrollment, with a median of 3 faints in 
that year, but 60% taking a medical placebo did not 
faint in the follow-up year. Similarly, in the double-
-blinded VPS II [21] and SYNPACE trials [22], the 
control inactive pacemaker arms had a marked 
reduction in syncope frequency compared to the 
preceding interval. Therefore, patients receiving 
either medical or device placebos have a marked 
reduction in syncope likelihood.
Effect of expectancy
These cases suggest that there is a powerful 
beneficial force embedded in the physician-patient 
relationship [23, 24], independent of whether a bio-
medical placebo is deliberately, even inadvertently, 
administered. It is also independent of whether 
the placebo is noninvasive or invasive. Is there 
a gradation within this effect?
One study compared invasive and non-invasive 
approaches to VVS [25]. This prospective, open-
-label, controlled trial assigned patients to medical 
(beta-blocker) or invasive (permanent cardiac pa-
cing) “treatment”. Both interventions were later 
shown in placebo-controlled randomized studies 
to have little or no true benefit. Both groups had 
a considerable decline in the frequency of symp-
toms in follow up, and the patients with pacema-
kers had far fewer outcomes that the patients with 
beta-blockers. Essentially, this was a randomized 
controlled trial of invasive vs. non-invasive placebo, 
and patients with the invasive placebo had a better 
outcome suggesting that treatment expectation is 
higher with invasive placebo.
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Effect of observer expectancy
In an informative meta-analysis, Sud et al. 
[26] reported that the likelihood of a syncopal 
recurrence was reduced in patients with active 
pacing vs. no implanted pacemaker; this was not 
significantly reduced in double-blinded randomized 
trials. Strikingly, in single-blinded studies in which 
the patients, but not physicians, were blinded to the 
treatment allocations, there was a large reduction 
in syncope likelihood. The authors concluded that 
the observed differences among study types were 
the result of physician behaviors leading to ascer-
tainment bias or to the expectancy effect.
Syncope, expectancy, and improvement
The variation in syncope frequency provides 
ample opportunity for understanding and using 
expectancy to benefit our patients. There is rela-
tively little evidence that a true placebo effect is at 
play: patients seem to improve about as much when 
they receive no specific treatment as when they 
receive inactive biomedical treatment regardless of 
the study type (observational vs. randomized), or 
the control arm. The common theme is that they 
are seen in specialty clinics providing a unique 
value of and expectations attached to the syncope 
“expert”.
Implications for understanding  
and treating syncope
These studies raise several interesting que-
stions concerning the natural history and treatment 
of syncope. We have shown that patients present 
for specialist assessment after a recent and mark-
ed worsening in syncope frequency [27], and that 
their syncope frequency after assessment can be 
predicted by their recent syncope frequency, and 
not syncope frequencies in the distant past [28]. 
We also show that syncope recurrence can improve 
substantially based on expectancy.
This raises the converse issue: why do people 
worsen? One possibility is that patients, for reasons 
unknown, develop negative subject expectancy, 
and subconsciously, anticipate or expect that they 
will faint again. That is, the first faint of a cluster 
is sporadic, then negative subject expectancy 
sustains the cluster, and positive observer and 
possibly subject expectancy reduces or eliminates 
syncope frequency.
Understanding syncope variation will have 
an impact on the structure of randomized clinical 
trials. It may be that patients should be screened 
first for susceptibility to expectancy, possibly with 
genetic screening. This would allow focus only on 
patients unlikely to respond to conservative mea-
sures, and this would have a major impact on power 
calculations and possibly on study feasibility. VVS 
requiring biomedical intervention may become 
a rare disease!
There may also be genetic and mechanistic 
implications [15, 16]. Genes with known associa-
tion with the placebo response also have plausible 
connections to VVS. Is there an unusually strong 
connection between VVS and expectancy and, if 
so, can the course of VVS be modified by therapies 
targeting the expectancy effects? This will raise 
a host of ethical issues, given the close interactions 
among observer and subject expectancy and the 
possible use of enthusiastically positive shams to 
effect a successful outcome. Conversely, are there 
patients who will purposely fail any expectancy or 
drug effects? That is also conceivable.
Ethics of placebo in clinical practice
Many clinicians are unwilling to use placebos 
that require active concealment or deception. On 
the one hand, clinicians are expected to respect 
their patient’s autonomy and informed consent 
whereas, on the other hand, harnessing the power 
of placebo may require deception. We contend that 
at least for VVS, the argument may be irrelevant, 
in that for suppressing VVS, physician-patient re-
lationship is critical. The biomedical intervention 
may be needed in only a residual minority. Indeed, 
Margo [8] recently suggested that the physician is 
a placebo.
Placebo in practice
Lichtenberg et al. [29] argue that the “placebo 
is deception only for those who would reduce treat-
ment to a purely biomedical pursuit”. Physicians 
intervene in many non-biomedical ways in caring 
for their patient — including assurance, persona-
lity, encouragement, offers to help and resolving 
uncertainty. In this light, the expectancy effect is 
just one in a spectrum of intangible ways a physi-
cian helps improve patient health.
Lichtenberg et al. [29] suggested when pla-
cebo use is acceptable, when the intent is to help 
patients and not silence them, when ineffective pla-
cebos should be withdrawn, and when they do not 
supplant proven therapies. Olshansky [23] argued 
that if the placebo effect is strong, the risk of harm 
is low, and other treatment options are limited, the 
use of placebo may be justified regardless of its 
deceptive underpinnings. One could argue that all 
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of these criteria are met in patients with recurrent 
syncope, especially given how powerful the effect 
appears to be.
Counterarguments to placebo use also require 
consideration. Asai and Kadooka [30] raised several 
major objections. The act of prescribing a deceptive 
placebo prevents true informed consent. Secondly, 
for placebos to be at all ethical they would need 
to work. A meta-analysis of 114 randomized trials 
in which patients received either placebo or no 
treatment suggests that this may not be the case 
[10]. However, this would be irrelevant if the no-
minal “no-treatment” featured earnest observer 
expectancy. Thirdly, included in the risks of placebo 
administration should be the consequences of 
a breakdown in physician-patient trust, but again 
this would be irrelevant if observer expectancy is 
the intervention. Finally, the authors argue that 
deception in placebo opposes the idea of dignity 
and may lead to patient’s unhappiness.
Expectancy and practice
The effect of expectancy is real, not due to pla-
cebo. Indeed, the term placebo frequently carries 
vaguely negative connotations in this syndrome. 
Rather, temporal variation and the expectancy 
effect reflect fundamental aspects of the genetics, 
physiology, and treatment of VVS.
This understanding should have a liberating 
effect on physicians’ attitudes and practice. Pa-
tients do not need to be deceived with intentional 
placebos; indeed, deliberate deception is probably 
irrelevant. Virtually nothing is taught in medical 
schools or postgraduate training about placebo 
effects and the effect of physicians’ attitudes and 
behaviors, yet this seems critical for effective 
therapy in VVS. Expectancy indicates that patients 
respond better when physicians are optimistic and 
positive about recommendations. The glass should 
always be half-full, and not half empty. For example, 
we might state that the treatment works well in 
many or most patients (be honest), and that we 
expect that it will work well for the person across 
the desk. We, ourselves, are forces for good, in 
addition to whatever biomedical treatments and 
benefits are available.
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